Most people assume that entering the pharmaceutical industry requires a manufacturing plant, expensive machinery, quality-control laboratories and a large technical team.
And for companies that manufacture medicines themselves, those requirements are very real.
However, not every pharmaceutical business owns the facility that manufactures its products.
Many pharmaceutical companies commercialise products by partnering with licensed third-party manufacturers that already possess the required manufacturing infrastructure, systems and capabilities.
This arrangement is commonly referred to as contract manufacturing or third-party manufacturing.
It allows a company to focus on product selection, branding, distribution and commercial execution while outsourcing manufacturing operations to a specialised manufacturing partner.
But there is an important distinction that is often missed.
Outsourcing manufacturing does not eliminate regulatory, quality or commercial responsibilities.
And the growth of India's contract manufacturing ecosystem does not automatically mean every pharma startup will succeed.
Understanding that distinction is essential before considering an asset-light pharmaceutical business model.
Reality Check
Many people assume manufacturing is the hardest part of building a pharmaceutical business.
In reality, manufacturing capacity is often easier to access than market demand.
A contract manufacturer can manufacture a product.
They generally cannot provide:
- Doctor adoption
- Distributor relationships
- Retail placement
- Institutional contracts
- Market demand
Product differentiation
That is why many pharmaceutical businesses struggle not because they cannot manufacture products, but because they cannot build sustainable distribution and demand.
This distinction is important before considering an asset-light pharmaceutical business model.
What Is Pharmaceutical Contract Manufacturing?
Contract manufacturing refers to an arrangement in which one pharmaceutical company engages another licensed manufacturing organisation to manufacture products on its behalf.
The manufacturing partner already has the infrastructure, equipment, manufacturing systems and licences required for the products it is authorised to produce.
Instead of building everything from scratch, the brand owner uses the manufacturing partner's existing capabilities.
This model is commonly referred to as third-party manufacturing in the Indian pharmaceutical industry.
The exact regulatory and contractual structure can vary depending on the product category, manufacturing arrangement, applicable licences and relevant legal requirements.
Contract Manufacturing, CDMO and CRDMO Are Not the Same Thing
These terms are often used interchangeably, but they describe different segments of the pharmaceutical outsourcing industry.
Contract Manufacturing
A company outsources manufacturing to another licensed manufacturer.
CDMO (Contract Development and Manufacturing Organisation)
The service provider may support both product-development and manufacturing activities.
CRDMO (Contract Research, Development and Manufacturing Organisation)
The provider may support research, development and manufacturing activities across the pharmaceutical value chain.
This distinction matters because many industry growth figures refer specifically to CRDMOs rather than traditional third-party manufacturing operations.
According to Unleashing the Tiger: Indian CRDMO Sector 2025, published by Boston Consulting Group (BCG) and IPSO, India's CRDMO sector is estimated at approximately $3-3.5 billion and could potentially grow to $22-25 billion by 2035.
Why Would a Pharma Company Outsource Manufacturing?
Building a pharmaceutical manufacturing facility is not simply a matter of buying machines and renting a building.
A manufacturing operation can involve:
- Manufacturing infrastructure
- Quality-control systems
- Qualified technical personnel
- Regulatory compliance
- Documentation systems
- Testing facilities
- Quality-management systems
- Equipment maintenance
- Utilities and environmental controls
- Validation and other technical requirements
For a new business, building these capabilities from scratch can require substantial capital and specialised expertise.
Contract manufacturing changes the starting point.
Instead of asking:
"How do I build a pharmaceutical factory?"
the entrepreneur can ask:
"Which products can I build a viable business around, and which compliant manufacturing partner can produce them?"
That is the fundamental idea behind the asset-light model.
How Does the Asset-Light Pharma Model Work?
A simplified model looks like this:
Brand Owner
↓
Product Selection
↓
Regulatory & Commercial Arrangements
↓
Licensed Contract Manufacturer
↓
- Manufacturing
↓
Testing & Quality Processes
↓
Finished Product
↓
Distribution
↓
Market
The entrepreneur does not necessarily need to own a manufacturing plant.
Instead, manufacturing capability is accessed through a licensed third-party partner operating within the applicable regulatory framework.
This can reduce the amount of capital tied up in manufacturing infrastructure.
But it does not eliminate regulatory, commercial or quality responsibilities.
What Does the Brand Owner Actually Do?
This is where the asset-light model is often misunderstood.
An entrepreneur does not simply place a logo on a medicine and start selling it.
Depending on the product and business structure, responsibilities may include:
Product Selection
Choosing products based on market demand, competition, therapeutic focus and commercial opportunity.
Branding
Building positioning, product identity and commercial strategy.
Distribution
Developing channels through distributors, stockists, retailers, hospitals or institutions.
Regulatory Coordination
Understanding approvals, licences, labelling requirements and applicable compliance obligations.
Quality Oversight
Working with manufacturing partners to ensure quality expectations and contractual requirements are clearly defined and monitored.
Commercial Management
Managing pricing, inventory, working capital, sales activities and customer relationships.
The model may be asset-light.
It is not responsibility-light.
What Does the Contract Manufacturer Do?
The manufacturing partner provides the manufacturing capability.
Depending on the arrangement, responsibilities may include:
- Manufacturing agreed products
- Maintaining manufacturing facilities
- Operating quality systems
- Conducting required testing
- Maintaining manufacturing documentation
- Following applicable manufacturing standards
- Supporting inspections and regulatory documentation where required
The division of responsibilities should be clearly defined through commercial agreements and quality agreements.
This is why selecting the right manufacturing partner is one of the most important decisions in the model.
What Contract Manufacturing Does Not Solve
One of the biggest misconceptions about contract manufacturing is that it solves the difficult part of the business.
In many cases, manufacturing is easier to outsource than commercial execution.
Contract manufacturing does not automatically provide:
- Product demand
- Prescription generation
- Doctor adoption
- Distributor relationships
- Retail shelf space
- Institutional contracts
- Regulatory approvals
Working capital
- Competitive differentiation
A manufacturing partner can manufacture the product.
The market still has to buy it.
Do You Need to Own a Factory?
Not necessarily.
A company may commercialise pharmaceutical products without owning a manufacturing facility by partnering with licensed manufacturers, provided the applicable regulatory and contractual requirements are satisfied.
This shifts the entrepreneur's focus toward:
Product + Brand + Distribution + Market Access
instead of:
Land + Plant + Machinery + Manufacturing Operations
However, this does not mean starting a pharmaceutical business requires very little capital.
Product sourcing, inventory, packaging, marketing, distribution, regulatory compliance activities and working-capital requirements can still be substantial.
Is the Pharma Market Already Crowded?
This is where many new entrants make mistakes.
A growing pharmaceutical market does not automatically mean launching another brand will be easy.
The challenge is not only manufacturing the product.
You also need distributors, stockists, retailers and ultimately customers willing to buy it.
Before launching a product, it can be useful to speak with pharma distributors and stockists in your target market.
Questions worth asking include:
- Which therapeutic categories are already crowded?
- Which products move quickly?
- What margins are generally expected?
- What order quantities are practical?
- Are retailers willing to add another brand?
- Which categories appear underserved?
This market feedback can help test a business idea before making significant investments in inventory, branding and marketing.
Because the real business question is:
Can you create demand and successfully get the product into the market?
A factory may solve a manufacturing problem.
It does not solve a distribution problem.
Why Is This Model Becoming More Relevant?
The pharmaceutical industry is becoming increasingly specialised.
Drug development and manufacturing often require specialised expertise, infrastructure and capabilities.
At the same time, pharmaceutical companies increasingly use external partners for research, development and manufacturing activities.
According to the BCG-IPSO report, India's CRDMO sector is estimated at approximately $3-3.5 billion today and could potentially reach $22-25 billion by 2035.
However, growth in the CRDMO industry does not automatically translate into success for pharmaceutical marketing companies.
Commercial success still depends on product strategy, quality, distribution and execution.
What About Regulatory Compliance?
This is not an area entrepreneurs should treat casually.
In India, the manufacture, sale and distribution of drugs are regulated under the Drugs and Cosmetics Act, 1940 and the Drugs and Cosmetics Rules, 1945, along with other applicable regulatory requirements.
Depending on the product category, requirements may relate to:
- Manufacturing licences
- Product approvals or permissions
- Labelling requirements
- Quality standards
- Testing
- Documentation
- Storage and distribution
- Advertising and promotion
- Pharmacovigilance and post-market obligations, where applicable
The exact requirements depend heavily on the product category and business structure involved.
For example, pharmaceutical formulations, nutraceuticals, cosmetics and medical devices may be subject to different regulatory frameworks.
Businesses should not assume that outsourcing manufacturing automatically transfers all compliance obligations to the manufacturing partner.
Responsibility allocation depends on the applicable legal framework, product category, licences involved and contractual arrangements.
The Biggest Advantage of the Asset-Light Model
The primary advantage is not simply avoiding machinery purchases.
It is capital allocation.
A traditional manufacturing approach may require substantial investment in:
- Manufacturing facilities
- Production equipment
- Infrastructure
- Maintenance
An asset-light approach may allow more capital to be allocated toward:
- Product portfolio expansion
- Market research
Branding
Distribution
- Sales
- Inventory
- Customer acquisition
Working capital
The entrepreneur is effectively accessing manufacturing capacity without building all that capacity from scratch.
But There Is a Catch
Outsourcing manufacturing does not eliminate business risk.
It creates a different set of risks.
Manufacturing Quality
Your brand may depend heavily on the quality systems and reliability of the manufacturing partner.
Supply Disruption
Production delays, capacity constraints or compliance issues can affect product availability.
Minimum Order Quantities
Manufacturers may require production minimums, which can increase working-capital requirements.
Product Differentiation
Multiple brands may use similar manufacturing capabilities.
Competitive advantage may need to come from distribution, positioning or customer relationships.
Regulatory Responsibility
Not all compliance obligations transfer to the manufacturer.
Working Capital
Inventory, packaging, marketing and receivables can still require significant funding.
Asset-light does not mean low-risk.
Three Common Pharma Business Models
1. Manufacturing Company
The company owns manufacturing infrastructure and produces pharmaceutical products itself.
Primary focus:
- Production
- Quality systems
- Regulatory inspections
- Capacity utilisation
2. Marketing Company
The company owns brands but outsources manufacturing.
Primary focus:
- Product portfolio
Branding
Distribution
- Sales
- Market development
3. Integrated Pharmaceutical Company
The company owns both manufacturing capabilities and product brands.
Primary focus:
- End-to-end control
- Manufacturing
- Commercial execution
- Portfolio expansion
Each model involves different capital requirements, regulatory responsibilities and operational complexity.
Is Contract Manufacturing a Shortcut Into Pharma?
Not exactly.
It is better understood as a different business model.
You are replacing some manufacturing investment with reliance on an external manufacturing ecosystem.
That can be attractive for entrepreneurs who want to build a pharmaceutical business without immediately investing in their own plant.
But the competitive advantage still has to come from somewhere.
It may come from:
- Better product selection
- Stronger distribution
- A focused therapeutic niche
- Better customer relationships
- Stronger branding
- Better market intelligence
- Superior execution
Simply finding a manufacturer and placing a brand name on a product is not, by itself, a sustainable strategy.
FAQs
Can I start a pharmaceutical company without owning a manufacturing plant?
Potentially, yes. Contract manufacturing may allow a business to commercialise products through licensed manufacturing partners, subject to applicable regulatory and contractual requirements.
Does contract manufacturing eliminate regulatory compliance?
No. Outsourcing manufacturing does not eliminate compliance obligations. The requirements depend on the product category, business structure and applicable regulations.
Is contract manufacturing cheaper than owning a factory?
It can reduce upfront investment in manufacturing infrastructure, but inventory, compliance, marketing, distribution and working-capital requirements still need to be considered.
Can a startup use a third-party manufacturer?
Potentially, yes, provided applicable regulatory requirements are satisfied and the chosen manufacturing partner is appropriately licensed.
Is India's CRDMO market already worth $25 billion?
No. According to the BCG-IPSO estimate, India's CRDMO sector is currently valued at approximately $3-3.5 billion and could potentially grow to $22-25 billion by 2035.
Is owning a pharmaceutical factory still a good business?
It can be. However, owning a manufacturing company and running an asset-light pharmaceutical marketing business are fundamentally different models with different capital requirements, expertise requirements and risk profiles.
Final Takeaway
Contract manufacturing has changed how businesses can participate in the pharmaceutical industry.
A company does not necessarily need to own a manufacturing facility to commercialise pharmaceutical products. By partnering with licensed manufacturers, businesses can access existing manufacturing capabilities without making the same level of investment required to build and operate a manufacturing plant.
However, this should not be confused with an easy path into pharma.
Manufacturing can be outsourced. Market demand cannot.
The businesses that succeed are usually not the ones with the biggest factories. They are the ones that understand product selection, regulatory compliance, quality oversight, market access, distribution and commercial execution.
The most important question is therefore not:
"Do I need a factory?"
It is:
"Which parts of the pharmaceutical value chain should I own, and which parts should specialised partners perform?"
That is the real strategic decision behind the asset-light pharmaceutical model.
Important Note
This article is provided for informational and educational purposes only and should not be construed as legal, regulatory, investment or professional advice. The feasibility of any pharmaceutical contract-manufacturing model depends on the specific product category, licences, approvals, contractual arrangements and applicable laws involved. Businesses should seek appropriate professional advice before entering the pharmaceutical industry.